| abstract |
This invention relates to a novel class of glycolic compounds which contain a linear backbone having four contiguous oxygen-substituted methine carbons. The compounds of this invention inhibit the ability of aspartyl protease from HIV to catalyze the hydrolysis of peptides. These novel compounds can be used to reduce production of infectious virions from chronically infected cells and can inhibit the further infection of host cells. As such, they are useful as therapeutic agents to treat acquired immunodefiency syndrom (AIDS), as well as AIDS-related complex (ARC), AIDS-related dementia, and non-symptomatic HIV infection. |